The aberrant immune response in AMD patients is at least partially genetically mediated by polymorphisms at two genetic loci, complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2), both of which have been strongly implicated in disease initiation and progression5–7. This evidence concerns the gene ARMS2 and age-related macular degeneration.